Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results

被引：0
|
作者：
Muggia, F. M. [1 ,2 ]
Boyd, L. [1 ,2 ]
Liebes, L. [1 ,2 ]
Downey, A. [1 ,2 ]
Muller, C. [1 ,2 ]
Pothuri, B. [1 ,2 ]
Blank, S. [1 ,2 ]
Rutledge, T. [1 ,2 ]
Fishman, D. [1 ,2 ]
Verschraegen, C. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] Univ New Mexico, Albuquerque, NM 87131 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5548
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND WEEKLY PACLITAXEL (T) AS FIRST-LINE TREATMENT IN METASTATIC BREAST CANCER (MBC)
    Badalamenti, Giuseppe
    Valerio, Maria Rosaria
    Rinaldi, Gaetana
    Arcara, Carlo
    Cicero, Giuseppe
    Vizzini, Laura
    Travagliato, Maria Grazia
    Intrivici, Chiara
    Russo, Antonio
    Gulotta, Gaspare
    Gebbia, Nicola
    Fulfaro, Fabio
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [32] Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
    Fiegl, Michael
    Mlineritsch, Brigitte
    Hubalek, Michael
    Bartsch, Rupert
    Pluschnig, Ursula
    Steger, Guenther G.
    BMC CANCER, 2011, 11
  • [33] Epidemiologic study to evaluate the treatment of palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD).
    Gonzalvez, M. L.
    Diaz, N.
    Redondo, A.
    Calvo, E. G.
    Illarramendi, J. J.
    Munarriz, B.
    Del Campo, J.
    Castellanos Diez, J.
    Santaballa, A.
    Lopez-Vivanco, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial
    Ferrero, J. -M.
    Weber, B.
    Geay, J. -F.
    Lepille, D.
    Orfeuvre, H.
    Combe, M.
    Mayer, F.
    Leduc, B.
    Bourgeois, H.
    Paraiso, D.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 263 - 268
  • [35] Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
    Michael Fiegl
    Brigitte Mlineritsch
    Michael Hubalek
    Rupert Bartsch
    Ursula Pluschnig
    Günther G Steger
    BMC Cancer, 11
  • [36] Outcomes of the combination trabectedin and pegylated liposomal doxorubicin (T-PLD) in recurrent platinum-sensitive ovarian cancer (OC): a GINECO cohort study
    Selle, F.
    Heudel, P-E.
    Tazi, Y.
    Pozet, A.
    Hardy-Bessard, A-C.
    Meunier, J.
    Gladieff, L.
    Lotz, J-P.
    Provansal, M.
    Augereau, P.
    Frenel, J-S.
    Bonichon-Lamichhane, N.
    Orfeuvre, H.
    Pommeret, F.
    Torres-Macque, M.
    Kalbacher, E.
    Roemer-Becuwe, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: Results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik, Guelten
    Koensgen, Dominique
    Hindenburg, Hans-Joachim
    Klare, Peter
    Schmalfeldt, Barbara
    Lichtenegger, Werner
    Chekerov, Radoslav
    Al-Batran, Salah-Eddin
    Neumann, Ulf
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2008, 28 (2B) : 1329 - 1334
  • [38] PALMAR-PLANTAR ERYTHRODYSESTHESIA (PPE) IN PATIENTS (PTS) WITH OVARIAN CANCER (OC) OR METASTATIC BREAST CANCER (MBC) TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD): AN OBSERVATIONAL STUDY
    Gonzalvez, M. L.
    Diaz, N.
    Redondo, A.
    Calvo, E. G.
    Illarramendi, J.
    Munarriz, B.
    Del Campo, J. M.
    Diez, J. Castellanos
    Santaballa, A.
    Lopez-Vivanco, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 389 - 389
  • [39] Weekly paclitaxel (T) and pegylated liposomal doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.
    Fulfaro, F
    Valerio, MR
    Badalamenti, G
    Arcara, C
    Cicero, G
    Intrivici, C
    Crosta, A
    Sciortino, C
    Russo, A
    Gebbia, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 53S - 53S
  • [40] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC)
    Mel, J. R., Sr.
    Ramos, M.
    Cueva, J.
    Castellanos, J.
    Almanza, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345